Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000131.xml
Synfacts 2021; 17(10): 1071
DOI: 10.1055/s-0040-1720181
DOI: 10.1055/s-0040-1720181
Synthesis of Natural Products and Potential Drugs
Synthesis of Sotorasib
Kargbo RB.
Usona Institute, San Luis Obispo, USA
Improved Synthesis of New FDA-Approved Treatment for KRAS G12C Mutation in Non-small Cell Lung Cancer.
ACS Med. Chem. Lett. 2021;
12: 1186-1187
DOI: 10.1021/acsmedchemlett.1c00330
Improved Synthesis of New FDA-Approved Treatment for KRAS G12C Mutation in Non-small Cell Lung Cancer.
ACS Med. Chem. Lett. 2021;
12: 1186-1187
DOI: 10.1021/acsmedchemlett.1c00330
Significance
Sotorasib (AMG 510, Lumakras) is the first ever FDA-approved drug that inhibits KRAS, a cancer target that has been termed “undruggable” even after over 40 years of cancer research. It was approved for KRAS G12C-mutated non-small cell lung cancer (NSCLC).
#
Comment
Urea D cyclized to give rac-dione E as a mixture of atropisomers in 41% yield over three steps. Chiral separation via the (+)-2,3-dibenzoyl-d-tartrate salt of rac-dione E led to M-dione M-F in 37% yield over two steps. For experimental details, see: WO 2021 097207 A1 and WO 2020 232130 A1.
#
#
Publication History
Article published online:
17 September 2021
© 2021. Thieme. All rights reserved
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany